Outcome of Annual General Meeting of May 22, 2019
Innate Pharma announces publication on next generation immunotherapies targeting the adenosine pathway in “Cell Reports”
Innate Pharma First Quarter 2019 Report
Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
Number of shares and voting rights of Innate Pharma as at April 18, 2019
Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
Innate Pharma announces the appointment of Jennifer Butler as Executive Vice President, General Manager, US
Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
Innate Pharma receives FDA fast track designation for IPH4102 in relapsed or refractory Sézary syndrome
